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Influenza virus RNA polymerase is a heterotrimeric complex consisting of PB1, PB2, and PA subunits. These polymerase subunits accumulate
in the nucleus of infected cells. We report here that PB2, from both human and avian influenza viruses, could also localize to mitochondria in
transfected cells. Importantly, cells infected with influenza A virus also displayed mitochondrial PB2. We show that an N-terminal motif composed
of 120 amino acids is sufficient for localization of PB2 to mitochondria. In particular, leucine residues at positions 7 and 10 were essential for
mitochondrial targeting. Recombinant influenza A/WSN/33 viruses expressing PB2 proteins with L7A and/or L10A mutations showed reduced
viral titers, but unaffected levels of transcription, replication, and protein expression. The introduction of L7A and/or L10A mutations into
recombinant viruses correlated with reduced mitochondrial membrane potential in infected cells, suggesting that mitochondrial localization of PB2
contributes to the preservation of mitochondrial function during influenza virus infection.
D 2005 Elsevier Inc. All rights reserved.Keywords: Influenza virus; RNA polymerase; Transcription; Polymerase basic protein 2 (PB2); Mitochondria; Mitochondrial-targeting signal; Mitochondrial
membrane potential; ApoptosisIntroduction
Influenza viruses are enveloped viruses of the Orthomyx-
oviridae, with a single-stranded, segmented RNA genome of
negative polarity. Each RNA segment is packaged into
ribonucleoprotein (RNP) complexes with viral nucleoprotein
(NP) and the viral RNA polymerase. The viral RNA
polymerase consists of three subunits, polymerase basic
protein 1 (PB1), polymerase basic protein 2 (PB2), and
polymerase acidic protein (PA), which together are respon-
sible for both transcription of virus encoded genes and
replication of the viral genome (Neumann et al., 2004). PB1
functions as the viral polymerase and contains motifs similar
to other RNA-dependent RNA polymerases (Biswas and
Nayak, 1994). PB1 can bind to the promoter sequences of
both vRNA and cRNA and, depending on its interaction with
RNA, can endonucleolytically cleave capped RNA (Li et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.08.041
* Corresponding author. Fax: +44 1865 275556.
E-mail address: ervin.fodor@path.ox.ac.uk (E. Fodor).2001). PA has been associated with the proteolysis of both
host and viral proteins (Hara et al., 2001; Sanz-Ezquerro et
al., 1995), although the physiological significance of this
observation is unclear. PA is also important for endonuclease
cleavage of capped RNA primers (Fodor et al., 2002) and as
an elongation factor in viral RNA synthesis (Fodor et al.,
2003).
PB2 has a key role in viral mRNA synthesis as it can
recognize and bind to the cap structures of host mRNAs
(Blaas et al., 1982; Honda et al., 1999; Ulmanen et al.,
1981). Two aromatic amino acid residues at positions 363
and 404 have been proposed to be involved in cap binding
by forming an Faromatic sandwich_ (Fechter et al., 2003).
Another report has suggested that the cap binding domain of
PB2 is localized to a tryptophan rich region between amino
acids 533 and 564 (Li et al., 2001), and a further study
suggested a second cap binding site between residues 242
and 252 (Honda et al., 1999). A role for PB2 in viral
replication is suggested by the observation that mutations in
the amino terminus of the protein specifically affect
replication but not transcription (Gastaminza et al., 2003).6) 492 – 508
www.e
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and pathogenicity of influenza virus infection. In 1997, an
H5N1 avian influenza virus with a high mortality rate was
isolated from patients in Hong Kong. Virus isolates fell into
two groups based on their pathogenicity in mice, and it was
demonstrated that the PB2 gene determined whether the
virus caused an avirulent, or a systemic, highly virulent
infection (Hatta et al., 2001). Amino acid position 627 of
PB2 was identified as being responsible for this difference in
virulence, confirming earlier work suggesting a role for this
residue in determining the efficiency of an infection with
avian influenza in mammalian cell lines (Subbarao et al.,
1993). Further work suggests residue 627 of PB2 affects the
spread of virus infection to non-respiratory organs, and the
ability to support efficient viral replication (Shinya et al.,
2004). Other regions of the PB2 protein have also been
identified as being important in overcoming an abortive
infection of avian influenza viruses in mammalian cell lines
(Yao et al., 2001).
Extensive study of the interactions between the three
polymerase subunits indicates that the PB1 subunit is capable
of interacting with both PB2 and PA, but no direct interaction
between PA and PB2 has been demonstrated (Digard et al.,
1989). However, the compact structure of the polymerase
complex, as determined by electron microscopy, would
suggest that contacts between all three polymerase subunits
are likely (Area et al., 2004). It has been proposed that the
interaction between PB2 and PB1 is mediated by the amino
terminal 249 amino acids of PB2 (Gonza´lez et al., 1996;
Toyoda et al., 1996), although work by others suggested
residues 206–259 of PB2 are particularly important (Ohtsu et
al., 2002). Recently, a second PB1 interaction site at the
carboxyl terminus of PB2 has been identified (Poole et al.,
2004). Interaction of PB1 with PA is mediated by the amino
terminus of PB1 and the carboxyl terminus of PA (Gonza´lez
et al., 1996; Ohtsu et al., 2002; Perez and Donis, 2001;
Toyoda et al., 1996; Zu¨rcher et al., 1996).
In virus infected cells, all three subunits of the
polymerase complex can be detected in the nucleus (Akkina
et al., 1987; Jones et al., 1986). This is not surprising, since
both viral transcription and replication occur in the nucleus
(Jackson et al., 1982). Using a variety of techniques, PB1, PA,
and PB2 have been expressed individually in cells. All three
proteins localized to the nucleus of cells in the absence of other
viral proteins (Mukaigawa and Nayak, 1991; Nath and Nayak,
1990; Nieto et al., 1994), suggesting that each polymerase
subunit contains intrinsic signals that mediate its nuclear
transport. Indeed, nuclear localization signals (NLS) have been
identified in all three polymerase subunits. Four basic residues
near the carboxyl terminus of PB2 were found to be necessary,
but not sufficient for nuclear localization of PB2 (Mukaigawa
and Nayak, 1991). Residues between amino acids 449 and 495
of PB2 are also suggested to be important for efficient nuclear
localization (Mukaigawa and Nayak, 1991). Similarly, two
regions in both the PB1 and PA protein may function as nuclear
localization signals (Nath and Nayak, 1990; Nieto et al., 1994).
A recent report, in which the localization of individuallyexpressed GFP-tagged polymerase subunits was examined,
suggested that an interaction between PB1 and PA is required
for their efficient nuclear accumulation (Fodor and Smith,
2004). Only PB2 was found to accumulate efficiently in the
nucleus in the absence of the other polymerase subunits (Fodor
and Smith, 2004). The authors of this report also observed that
low levels of PB2 localized to mitochondria, in addition to its
nuclear localization.
In this present study it is demonstrated that the PB2 protein
of the RNA polymerase complex of influenza viruses is
targeted to the mitochondria in both transfected cells, and cells
infected with virus. The mitochondrial-targeting signal (MTS)
of PB2 was localized to the amino terminus of the protein, and
fine mapping of the MTS indicated two conserved leucine
residues were essential for mitochondrial localization. Recom-
binant influenza A/WSN/33 viruses were generated in which
the identified leucine residues in PB2 were substituted with
alanine residues. The growth and replication properties of
these viruses were determined in both a mouse model and cell
culture. The effect of mitochondrial PB2 on the organelle’s
membrane potential was also investigated. The data obtained
suggest that mutations in the MTS of PB2, which prevent
translocation of the protein to mitochondria, lead to the
disruption of mitochondrial function during influenza virus
infection.
Results
Localization of influenza virus PB2
While studying the intracellular localization of polymerase
subunits of influenza viruses, it was noted that PB2 localized to
a discrete cytoplasmic site (Fodor and Smith, 2004) in addition
to its previously described nuclear localization (Jones et al.,
1986; Mukaigawa and Nayak, 1991). To determine if this
localization was a general feature of PB2 proteins of different
influenza virus strains, Vero cells were transfected with
plasmids coding for the PB2 protein of influenza viruses A/
WSN/33, A/PR/8/34, A/Turkey/England/5092/91, and B/
AnnArbor/1/66. The localization of PB2 was analyzed by
indirect immunofluorescence with anti-PB2 antibody at 16
h post-transfection (Fig. 1A). In all cases a discrete cytoplasmic
signal was detected in addition to a stronger nuclear signal. It
was hypothesized that this cytoplasmic signal represented
localization of PB2 to mitochondria, and to confirm this
transfected cells were stained with MitoTracker Red, a
molecular probe that specifically labels mitochondria (Poot et
al., 1996) (Fig. 1A). It was apparent that the signal for the PB2
protein originating from each viral strain co-localized with the
mitochondrial MitoTracker Red signal. As a further indicator of
co-localization, PB2 protein and MitoTracker Red signal
intensities across a cellular distance (represented by white
lines in the merged images) were plotted together. The
mirroring of peaks in intensity between the PB2 protein and
MitoTracker Red signal confirms the co-localization of the two
(Fig. 1A). 67.8% of cells (78 out of 115) expressing the PB2
protein of influenza A/WSN/33 virus and 69.9% of cells (109
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virus displayed a mitochondrial localization of the protein. PB2
also co-localized with cytochrome c in cells transfected with
the expression plasmid for the PB2 protein of influenza A/
WSN/33 virus (Fig. 1B). Distribution of the protein to
mitochondria was also evident in Vero cells transfected with
constructs encoding GFP- or FLAG-tagged PB2 (data not
shown). This localization was not specific to the Vero cell line,
since similar results were recorded on 293T, HeLa, and Cos-7
cells (data not shown).
To determine if the PB2 protein of influenza was directed to
mitochondria during infection, Vero or MDCK cells wereFig. 1. Intracellular distribution of GFP-tagged and untagged PB2 in transfected an
derived from different influenza virus strains (indicated on the left). PB2 was detec
secondary antibodies (PB2). Cells were also stained with MitoTracker Red (MT) to
included (Merge). An intensity plot over a cellular distance (white line) of these merg
from influenza A/WSN/33 virus are shown in the PB2 panel. Cytochrome c was d
Cy3-conjugated secondary antibodies (Cyt c). An overlay of the two images (Mer
influenza A/WSN/33 virus, and MDCK cells infected with influenza A/PR/8/34
conjugated secondary antibodies (PB2). Mitochondria were labeled with MitoTrack
Uninfected Vero and MDCK cells, labeled with MitoTracker Red alone, are also incl
uninfected cells. Note that mitochondrial morphology is different between the two ce
for panels A and B were collected using a Zeiss Axioplan microscope. Images forinfected with influenza A/WSN/33 or A/PR/8/34 virus,
respectively. 8 h post-infection, mitochondria were labeled
with MitoTracker Red and PB2 localization was determined
(Fig. 1C). Both viruses demonstrated co-localization between
PB2 and MitoTracker Red, as determined from the merged
images and the intensity plots. 50.7% of Vero cells (153 out of
302) infected with influenza A/WSN/33 virus and 43.3% of
MDCK cells (101 out of 233) infected with influenza A/PR/8/
34 virus displayed a mitochondrial localization for PB2,
although the intensity of this mitochondrial signal differed
between individual cells (data not shown). It is also interesting
to note that mitochondrial morphology did not appear to bed infected cells. (A) Vero cells were transfected with plasmids encoding PB2
ted by staining with rabbit polyclonal anti-PB2 primary and FITC-conjugated
label the mitochondria, and an overlay of the PB2 and MitoTracker signals is
ed images is shown to the right. (B) Transfected Vero cells expressing PB2-GFP
etected after staining with a mouse monoclonal anti-cytochrome c primary and
ge) and an intensity plot is included on the right. (C) Vero cells infected with
virus. PB2 was detected with rabbit polyclonal anti-PB2 primary and FITC-
er Red (MT), and an overlay image (merge) and an intensity plot are included.
uded in the bottom panels to give an indication of mitochondrial morphology in
ll lines. In all panels, the calibration bar represents a distance of 10 Am. Images
panel C were taken using a Bio-Rad MRC 1024 confocal microscope.
Fig. 1 (continued).
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course experiment revealed that PB2 could be detected initially
only at the nucleus, from 3 h post-infection. By 6 h post-
infection, PB2 could be detected at both the nucleus and the
mitochondria (data not shown). Taken together, these results
suggest that mitochondrial targeting of PB2 is a general feature
of both human and avian influenza A and influenza B viruses.
Mapping the mitochondrial-targeting signal of PB2
To determinewhich region of PB2 possesses amitochondrial-
targeting signal (MTS), a panel of constructs from influenza A/
WSN/33 virus, encoding deletion mutants tagged with a carboxy
terminal GFP, was generated (Fig. 2A). These constructs were
transfected into Vero cells, mitochondria were stained with
MitoTracker Red, and PB2 localization was analyzed 16 h post-
transfection. Cells transfected with the control GFP plasmid
demonstrated diffuse green fluorescence throughout the cell (Fig.
2B). This is due to the lack of targeting signals in GFP and its
small size, which permits diffusion across the nuclear envelope.
In cells expressing full-length PB2-GFP, signal was detected in
the nucleus and mitochondria as demonstrated previously (see
above). Constructs expressing PB2 fragments 1–60 and 1–22
were found to exhibit GFP-like diffuse fluorescence, whereas
constructs expressing fragments 1–522, 1–281, 1–180, and 1–
120 exhibited either an exclusivelymitochondrial, or nuclear and
mitochondrial localization, depending on expression levels (Fig.
2A). An example of cells expressing low levels of fragment 1–
120 of PB2 displaying an exclusively mitochondrial localizationis shown in Fig. 2B. However, cells expressing higher levels of
these PB2 fragments show both mitochondrial and nuclear
signals most likely due to the ability of these small fragments to
diffuse across the nuclear envelope (results not shown). The fact
that PB2 fragments, when expressed at low levels, are preferen-
tially targeted to mitochondria (1–120 PB2-GFP, Fig. 2B)
indicates that the N-terminal region of PB2 must contain an
MTS.Constructs expressingPB2 fragments 181–759, 121–759,
61–759, and 23–759 exhibited nuclear localization only,
demonstrating a loss of the MTS (Figs. 2A and B). Taken
together, these results imply that the region of PB2 between
amino acids 1 and 120 is sufficient to target the protein to
mitochondria, and the amino terminal 22 amino acids are
necessary for mitochondrial localization. A targeting signal
located at the amino terminus of the protein is not surprising since
cellular proteins that are targeted to mitochondria are known to
have an MTS at their amino terminus (Stojanovski et al., 2003).
Further support for an amino terminal MTS was provided by
expressing a PB2 construct tagged with an amino terminal GFP.
This construct demonstrated nuclear and cytoplasmic localiza-
tion of PB2, without evidence of signal in the mitochondria. No
overlap between the PB2 signal and the MitoTracker Red signal
was detected in the intensity profiles (Fig. 2B). This suggests the
MTShadbeenmaskedby the addition of the amino terminalGFP.
Fine mapping of the MTS
Amino terminal MTSs are known to contain positively
charged, hydrophobic, and hydroxylated amino acid residues,
Fig. 2. Effect of N- and C-terminal deletions on the intracellular distribution of GFP-tagged PB2. (A) Diagrammatic representation of the panel of deletion mutants
created in a GFP-tagged PB2 expression vector. The numbers to the left indicate the amino acids of PB2 expressed, and the letters to the right indicate a nuclear (N),
nuclear and mitochondrial (N/M), or general (G) distribution of the protein in transfected Vero cells. (B) Vero cells transfected with the indicated PB2 deletion
constructs. GFP fluorescence was analyzed to examine PB2 localization (GFP), and cells were stained with MitoTracker Red (MT) to label mitochondria. An overlay
image combining the two signals (Merge) and an intensity plot over a cellular distance (white line) of this merged image is shown to the right. A calibration bar in
this panel represents a distance of 10 Am. All images were generated using a Bio-Rad MRC 1024 confocal microscope.
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1986). Another property of these sequences is their tendency
to form an amphipathic a-helix (Abe et al., 2000; Stojanovski
et al., 2003). The secondary structure for the amino terminal
120 amino acids of influenza A/WSN/33 virus PB2 protein
was predicted using the program JPred (http://www.compbio.
dundee.ac.uk/~www-jpred/). This predicted, with high proba-bility, an a-helical secondary structure between amino acids 1
and 13 of PB2, although an a-helix was predicted up to amino
acid 18 at lower probability (data not shown). A helical wheel
representation of PB2 amino acids 1–18 (Fig. 3) shows a high
proportion of positively charged and hydrophobic residues in
this region, including a number of serine, arginine, and leucine
residues.
Fig. 3. A helical wheel representation of the amino terminus of PB2 from
influenza A/WSN/33 virus. The first 18 amino acids are included. Positively
charged residues are labeled with a +, while hydrophobic residues are boxed in
grey. The sequence of amino acids is numbered in order. Conserved leucine
residues at positions 7 and 10 are indicated by arrows.
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of replacing arginine, serine, and leucine residues within the
predicted a-helix was examined. GFP-tagged PB2 constructs
were generated with the following point mutations: arginine
at amino acid positions 3, 8, or 15 replaced with an alanine
(R3A, R8A, R15A); leucine at positions 7 or 10 replaced
with an alanine (L7A, L10A); or serine at position 14
replaced with an alanine (S14A). These constructs were
expressed in Vero cells and the GFP signal was analyzed 16
h post-transfection. Replacement of either leucine residue at
position 7 or 10 was sufficient to disrupt MTS function,
whereas replacement of any single arginine or serine residue
had no effect on PB2 localization (Fig. 4A). A double
mutation where both leucines were replaced with alanines
abolished MTS function (L7L10A). These results were
confirmed using 293T and Cos-7 cells (data not shown).
This shows that the two leucine residues are required for the
mitochondrial targeting of PB2. Surprisingly, replacement of
a serine residue at position 12 with a proline (S12P), which
would disrupt part of the a-helix in the proposed MTS, did
not affect PB2 localization significantly (Fig. 4A). This
suggests that, in the context of a full-length PB2 protein,
some structural alteration within the predicted a-helix is
tolerated and does not effect mitochondrial targeting of PB2.
Using the alignment software ClustalW (http://www.ebi.
ac.uk/clustalw/), a selection of influenza PB2 protein
sequences collected from the Influenza Sequence Database
(http://www.flu.lanl.gov/) was compared. Within the pre-
dicted a-helix of the MTS of PB2, two leucine residues
were conserved in the majority of influenza A and B viruses.
The conserved leucine residues occur at amino acid positions7 and 10 in influenza A viruses, and at amino acid positions
9 and 12 in influenza B viruses (data not shown).
Generation of recombinant influenza A/WSN/33 viruses and
the effect of mutations in the MTS of PB2 on viral growth
The leucine to alanine point mutations were rescued into
recombinant influenza A/WSN/33 viruses using plasmid-based
reverse genetics (Fodor et al., 1999, 2002; Neumann et al.,
1999), to generate novel mutant A/WSN/33 viruses named
L7A, L10A, and L7L10A. The effect of these mutations on
PB2 localization, in the context of a viral infection, was studied
by infecting Vero cells with wild-type influenza A/WSN/33
virus, or the generated recombinants (Fig. 4B). In cells infected
with L7A, L10A, and L7L10A virus, PB2 localization to the
mitochondria was disrupted. PB2 could still be detected in the
nucleus, and some signal was also present in the cytoplasm of
some cells, as exemplified in the L7L10A panel (Fig. 4B).
However, this cytoplasmic signal did not appear to co-localize
with the signal produced by MitoTracker Red staining (Fig. 4B,
compare merge panels and intensity plots), indicating PB2 has
not been directed to the mitochondria in the cells infected with
the recombinant viruses.
To investigate the effect of replacing leucine residues in the
MTS of PB2 on viral growth, MDBK cells were infected with
either wild-type influenza A/WSN/33 virus, or the recombinant
viruses. Every 12 h samples of culture media were collected
and plaque assays performed to determine the viral titer. Wild-
type influenza A/WSN/33 virus reached a maximum titer at 48
h post-infection, which gradually declined over the next 24
h (Fig. 5A). All three recombinant viruses showed similar
growth kinetics, but the L7A and L10A viruses had a slightly
reduced peak titer as compared to the wild type, although this
difference was not statistically significant (1.1  107 pfu/ml
and 1.7  107 pfu/ml, respectively, as compared to 5.6  107
pfu/ml). The L7L10A virus peak titer was reduced more
significantly (3.3  106 pfu/ml as compared to 1.0  108 pfu/
ml; P = 0.01). Plaque sizes for each virus also varied. Wild-
type influenza A/WSN/33 virus produced plaques in the range
of 1.2 T 0.25 mm, whereas both the L7A and L10A viruses
showed marginally reduced plaque size at 1.1 T 0.23 mm (P =
0.1), and 1.0 T 0.25 mm (P = 0.006). The L7L10A virus
showed the greatest reduction with a plaque size of 0.8 T 0.23
mm (P = 0.0001) (data not shown). These results could suggest
that targeting of PB2 to mitochondria is required for a fully
functional viral life cycle. However, such a drop in viral titer
might also be caused by an effect of the leucine to alanine
mutations on the function of PB2 as a polymerase subunit (see
below).
Mutations in the MTS of PB2 have minimal effects on
polymerase activity, viral protein expression, and polymerase
complex formation
The amino terminus of PB2 has been suggested to be
involved in virus replication (Gastaminza et al., 2003). To
address the possibility that the leucine to alanine point
S.M. Carr et al. / Virology 344 (2006) 492–508498mutations described above affect the polymerase activity of
PB2, transcriptional and replicative activities of the recombi-
nant viruses were assayed by analyzing vRNA, mRNA, and
cRNA levels in infected cells by primer extension assays
(Fodor et al., 2002; Pleschka et al., 1996; Vreede et al., 2004).
The amount of each viral RNA species detected after infection
with the recombinant viruses was compared to those detected
after infection with the wild-type influenza A/WSN/33 virusFig. 4. Effect of point mutations in the MTS on the intracellular distribution of PB
tagged PB2 proteins containing amino acid substitutions. Arginine, serine, or leucine
fluorescence was analyzed to examine PB2 localization (GFP), and cells were st
combining the two signals (Merge) and an intensity plot over a cellular distance (wh
wild-type influenza A/WSN/33 or recombinant influenza A/WSN/33 viruses contain
after staining with mouse monoclonal anti-PB2 primary and Cy2-conjugated second
and an overlay image (Merge) and intensity plots are included. An example image
bottom panel, to give an indication of mitochondrial morphology in uninfected cells.
taken using a Zeiss Axioplan microscope.(Fig. 5B). The polymerase function of the L7A or L10A
influenza A/WSN/33 viruses was not reduced in this assay.
Indeed, the levels of all three RNA species were seen to
increase marginally in both cases [although this was
statistically significant only for the L10A virus; P = 0.01
(vRNA), P = 0.02 (mRNA), P = 0.003 (cRNA)]. Introduction
of both leucine to alanine point mutations in the L7L10A
influenza A/WSN/33 virus caused some reduction in poly-2 in transfected and infected cells. (A) Transfected Vero cells expressing GFP-
residues were substituted with alanine or proline at the indicated positions. GFP
ained with MitoTracker Red (MT) to label mitochondria. An overlay image
ite line) of this merged image is shown to the right. (B) Vero cells infected with
ing the indicated point mutations in their PB2 gene segment. PB2 was detected
ary antibodies (PB2). Mitochondria were labeled with MitoTracker Red (MT),
of uninfected Vero cells stained with MitoTracker Red alone is included in the
In each panel, a calibration bar represents a distance of 10 Am. All images were
Fig. 4 (continued).
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was not statistically significant [P = 0.2 (vRNA), P = 0.65
(mRNA), P = 0.19 (cRNA)]. Viral RNA species could not be
detected in mock infected cells (results not shown). These
results indicate that the introduction of point mutations into
the amino terminus of PB2 has not severely attenuated the
polymerase function of the subunit, or significantly reduced
the ability of the recombinant viruses to generate all three
viral RNA species.
Since introducing L7A, L10A, or L7L10A point mutations
into PB2 had no significant effect on viral mRNA production,
it would be expected that viral protein expression also
remains unaffected. To confirm this was the case, HeLa cells
were infected with either wild-type or one of the recombinant
influenza A/WSN/33 viruses. 16 h post-infection, cell lysates
were prepared and protein expression was analyzed by
Western blot using a selection of polyclonal antibodies
against specific viral proteins (Fig. 5C). The levels of PA,
PB2, NP, M1, and NS1 proteins detected were found to be
comparable between all the viruses. This result is in
agreement with the primer extension data and suggests that
the introduction of point mutations into the MTS of PB2 has
not affected viral protein expression. The reduced titers seen
with the recombinant influenza A/WSN/33 viruses in Fig. 5A
are therefore unlikely to be caused by reduced viral RNA orprotein levels. Since polymerase function is not significantly
reduced by the introduction of point mutations into the N-
terminus of PB2, it is unlikely that polymerase complex
formation between PB2, PB1, and PA is disrupted. Indeed,
PB2 proteins possessing L7A, L10A, or L7L10A point
mutations appeared to form a polymerase complex with
similar efficiency as a wild-type PB2 (data not shown), as
determined by the co-purification experiment detailed in the
Materials and methods.
Mutations in the MTS of PB2 affect the mitochondrial
membrane potential of cells
Since changes to polymerase activity or viral protein
expression are unlikely to be the cause of the reduced viral
titers associated with the L7A, L10A, and L7L10A recombi-
nant viruses, it was hypothesized that a mitochondria-associ-
ated function could be affected by the introduction of point
mutations into the MTS of PB2. As oxidative phosphorylation
proceeds on the inner membrane of mitochondria, a membrane
potential is generated (Newmeyer and Ferguson-Miller, 2003).
If PB2 accumulates at the mitochondria during a virus
infection, it is possible that there will be a detectable change
in this membrane potential as PB2 alters or disrupts mitochon-
drial function or membrane integrity. To investigate this
Fig. 5. Effect of point mutations in the MTS of PB2 on the growth properties of recombinant influenza viruses. (A) Growth curves of wild-type influenza A/WSN/33
or recombinant influenza A/WSN/33 viruses possessing the indicated point mutations in their PB2 gene segment. MDBK cells were infected with the appropriate
virus and samples of culture medium were collected every 12 h to determine viral titers by plaque assay. Mean titers from 4 experiments are displayed, with standard
deviations shown. Where standard deviations are not visible, they are contained within the symbol used to denote the mean titer. (B) Primer extension assays of
vRNA, mRNA, and cRNA isolated from MDBK cells infected with wild-type or the indicated recombinant influenza A/WSN/33 viruses. vRNA, mRNA, and cRNA
signals for each of the viruses from 3 independent assays were measured on a fluorescent image analyzer, and values were converted to percentage activity as
compared to wild-type influenza A/WSN/33. Standard deviations are shown. (C) Western blots of extracts from HeLa cells infected for 16 h with wild-type influenza
A/WSN/33 [at an m.o.i. of 2 (wt2) or 4 (wt4)] or the indicated recombinant influenza A/WSN/33 viruses (at an m.o.i. of 2). Viral PA, PB2, and NS1 proteins were
detected with appropriate rabbit polyclonal antibodies. Viral NP and M1 proteins were detected with a rabbit polyclonal anti-influenza antibody. Sizes in kilodaltons
are indicated on the left.
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recombinant influenza A/WSN/33 viruses. After infection,
mitochondria were stained with the mitochondrion-selective
dye TMRE, the accumulation of which is driven by membrane
potential (Scaduto and Grotyohann, 1999). Flow cytometry
analysis permits changes in the mitochondrial membrane
potential in infected cells to be monitored at the single-cell
level. An example of the results obtained from a single
experiment is shown in Fig. 6A. The uninfected control
(TMRE) shows that a high proportion of cells stain efficiently
with TMRE, indicating that these cells have a normal
mitochondrial membrane potential. Treating cells with staur-
osporine (1 AM STR), a potent stimulator of apoptosis which
induces mitochondrial permeability changes and membrane
damage (Tafani et al., 2001) caused a dramatic reduction in
TMRE staining, indicating mitochondrial membrane potentialhad been affected. Cells infected with wild-type or recombinant
influenza A/WSN/33 viruses for 16 h showed an intermediate
effect on mitochondrial membrane potential, with the L10A
and L7L10A viruses causing the greatest disruption. Data from
several experiments were processed as described in Materials
and methods to generate the results presented in Fig. 6B. These
results indicate that introducing a single leucine to alanine
point mutation at amino acid position 7 or 10 in the PB2 gene
of influenza virus causes a significant increase in the
proportion of cells displaying disrupted mitochondrial mem-
brane potentials (compare wt and L7A, P = 0.0018; and wt and
L10A, P = 0.0001). Introduction of both point mutations
induces a more potent mitochondrial disruption (compare wt
and L7L10A; P < 0.0001). These experiments were also
performed on infected MDBK cells. TMRE labeling of the
cells was performed at 8 h rather than 16 h post-infection, since
Fig. 6. Effect of point mutations in the MTS of PB2 on the maintenance of mitochondrial membrane potential in infected cells. (A) Representative histograms
showing TMRE staining in 105 HeLa cells infected with wild-type (wt), or the indicated recombinant influenza A/WSN/33 viruses. Cells were infected at an m.o.i. of
4 and stained with TMRE at 16 h post-infection as described in Materials and methods. Alternatively, cells were treated with 1 AM staurosporine (STR) to induce
apoptosis. The percentages of cells showing a reduced mitochondrial membrane potential are shown at the top left of each histogram, while the percentages of cells
displaying a normal mitochondrial membrane potential are shown at the top right of each histogram. (B) Graphical representation of the effect of infection on the
mitochondrial membrane potential. The average percentage of cells showing a reduced mitochondrial membrane potential (mmp) from 3 independent assays on
HeLa cells are shown with standard deviations. These values were calculated as described in the Materials and methods.
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mitochondrial disruption after infection. Nevertheless, a
significantly greater proportion of cells displayed disrupted
mitochondrial membrane potential after infection with the
L7L10A recombinant virus than after infection with wild-type
influenza A/WSN/33 (data not shown). This suggests that
localization of the PB2 protein to mitochondria during an
influenza infection is important in the maintenance of
mitochondrial function.To exclude the possibility that the obtained results might be
influenced by small differences in virus particle number, a
range of viral loads was tested for each virus (see Materials and
methods). Changing the viral load had no further significant
effect on mitochondrial membrane potential for any of the
viruses (data not shown). Approximately 100% of cells were
found to be infected for each virus at an m.o.i. of 2, as
determined by fluorescence microscopy using polyclonal
antibodies reactive to NP and M1 (data not shown).
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In order to further characterize the effect that mutations in
the MTS of PB2 have on the properties of the virus, the
replication of recombinant influenza A/WSN/33 viruses was
studied in a mouse model. Groups of 5 BALB/c mice were
infected i.n. with 104 pfu of each virus, and survival rates and
changes in body weight were monitored daily (represented in
Figs. 7A and B). All mice showed signs of body weight loss
after infection with wild-type influenza A/WSN/33 and 4 out of
5 mice were euthanized by 11 days post-infection, due to the
extent of disease. Body weight loss after infection with theFig. 7. Pathogenicity and viral titers of wild-type and recombinant influenza
A/WSN/33 viruses in mice. Groups of 5 mice were infected i.n. with 104 pfu
of wild-type virus or the indicated recombinant influenza A/WSN/33 viruses.
(A) Numbers of surviving mice per group were recorded each day for up to 14
days post-infection. (B) Mice were weighed daily following infection and
body weights were compared with those on the day of infection. The average
body weight percentages of the surviving animals per group are represented.
Standard deviations are omitted for clarity. (C) Infected mice were sacrificed
at 3 and 6 days post-infection. After removal and homogenization of lungs,
viral titers were determined by plaque assay on MDBK cells. Average titers
and standard deviations from 3 mice are shown for each virus.recombinant viruses was moderate, but significant when
compared to the uninfected control (PBS) in most cases [P =
0.15 (L7A), P = 0.084 (L10A), P = 0.024 (L7L10A), P = 0.021
(wt) at 9 days post-infection]. The L7L10A recombinant virus
appears to induce slightly greater loss of body weight in mice
than either the L7A or L10A viruses, although the differences
between these three viruses were not significant. Infections
with the L10A or L7L10A viruses lead to 1 out of 5 mice
having to be euthanized by 9 days post-infection. Mice body
weights began to recover after 10 days post-infection with the
recombinant viruses, suggesting that the mice had cleared the
viruses by this time point.
Next, groups of 6 BALB/c mice were infected i.n. with 104
pfu of wild-type or recombinant influenza A/WSN/33 viruses.
Three and 6 days post-infection, the viral titers in the lungs of
groups of 3 mice were determined by plaque assay. Wild-type
influenza A/WSN/33 virus grew to a high titer in the lungs of
infected mice (approximately 2  106 pfu/ml at both time
points) (Fig. 7C). Titers in the lungs of mice infected with the
L7A and L10A recombinant viruses were one log lower
(approximately 2  105 pfu/ml at both time points), while
titers with the L7L10A virus were two logs lower (approxi-
mately 3  104 pfu/ml at both time points). The titers obtained
with the recombinant viruses were significantly different
compared to the titer obtained with the wild-type virus at 6
days post-infection [P = 0.008 (L7A), P = 0.006 (L10A), P =
0.005 (L7L10A)]. These results are comparable to the relative
titers presented in Fig. 5A. The attenuation in growth of the
recombinant viruses in the lungs of mice could explain why the
pathogenicity of these viruses is reduced compared to that of a
wild-type virus.
Discussion
The influenza virus PB2 protein is known to localize to the
nucleus of infected cells (Jones et al., 1986; Mukaigawa and
Nayak, 1991). In this report, we demonstrate that the PB2
subunit of the RNA polymerase also localizes to the
mitochondria. This is a general feature of influenza viruses,
since it was observed with both human and avian influenza A
virus, and influenza B virus PB2 subunits (Figs. 1A and B).
Significantly, mitochondrial localization of PB2 was also
observed in infected cells (Fig. 1C), indicating that such a
localization is not caused by over-expression of the protein in
a plasmid-based system. Approximately 40–50% of infected
cells demonstrated mitochondrial localization of PB2 (data
not shown). However, this value only represents the
percentage of cells displaying detectable levels of PB2 at
the mitochondria. It is likely that the percentage of cells with
mitochondrial PB2 is higher than this value due to the
detection threshold of the experiments performed here.
Indeed, PB2 cannot be visualized in the nucleus of cells at
2 h post-infection (data not shown), despite the fact that viral
RNA synthesis can be detected in infected cells at this time
point (Vreede et al., 2004), indicating that PB2 must be
present. It is apparent that the majority of PB2 localizes to the
nucleus of an infected cell, with much lower levels of protein
S.M. Carr et al. / Virology 344 (2006) 492–508 503detected in the mitochondria. This is possibly related to the
mechanism by which the PB2 protein is targeted to
mitochondria. The PB2 protein contains two discrete nuclear
localization signals (NLS) (Mukaigawa and Nayak, 1991), in
addition to the MTS described in this report. In the cytoplasm
of an infected cell, the NLS and MTS of newly synthesized
PB2 could compete to determine the localization of the
protein. The outcome is likely affected by interactions with
host factors, such as members of the nuclear import or
mitochondrial translocation machinery. A preferential interac-
tion between PB2 and the nuclear import apparatus would
explain the predominance of PB2 in the nucleus of infected
cells (Fig. 1C). The precise mitochondrial compartment to
which PB2 is localized in infected cells is unknown at this
stage, but higher resolution images obtained by electron
microscopy would permit this question to be resolved.
The location of the MTS in PB2 was determined by
deletion analysis, and the amino terminal 120 residues of PB2
were found to be sufficient for the mitochondrial localization
of a GFP-tagged PB2 peptide. Deletion of the N-terminal 22
amino acids, which prevented mitochondrial localization of
PB2, suggested these residues were essential for the MTS of
PB2 to function (Figs. 2A and B). An earlier study has also
demonstrated that a chemically synthesized peptide
corresponding to the first 22 amino acids of PB2 contains
sufficient information to mediate an interaction with isolated
mitochondria (Woodfin and Kazim, 1993). The results in this
earlier publication are not entirely consistent with our report.
Here it is shown that peptides comprising the amino terminal
22 or 60 residues of PB2, tagged with GFP, do not localize to
mitochondria when expressed in cells (Fig. 2A). However, the
GFP tag might have affected the folding of these short
peptides, disrupting a possible mitochondrial-targeting signal.
Alternatively, the strong, diffuse GFP-like signal seen with
these constructs may have masked a weaker mitochondrial
signal.
Within the amino terminal 120 residues of PB2, an a-helical
structure was predicted with high probability for the first 13
amino acids (data not shown), a region of the protein
containing a number of charged or hydrophobic residues
(Fig. 3). Such features are common to proteins targeted to
mitochondria (Stojanovski et al., 2003; von Heijne, 1986). Fine
mapping of the amino terminus of PB2 (Fig. 4A) identified two
leucine residues at positions 7 and 10 as being essential for
MTS function. These two leucine residues were found to be
conserved across influenza A and B viruses (data not shown).
Interestingly, leucine residues have been shown to be important
for the interaction of the mitochondrial import receptor Tom 20
with the targeting sequences of mitochondrial proteins such as
rat aldehyde dehydrogenase (Abe et al., 2000). Interactions
between mitochondrial receptors and MTS-containing proteins
are mediated by cytoplasmic chaperones, such as the heat
shock proteins (Stojanovski et al., 2003; Young et al., 2003).
These chaperones recognize the pre-sequence of the mitochon-
drial protein and help to maintain it in an import-competent
state. The PB2 protein of influenza A virus is known to
associate with Hsp90 (Momose et al., 2002) and Hsp70(J. Sharps and G. G. Brownlee, unpublished data). Both
chaperones could be involved in the translocation of PB2 to
mitochondria.
Point mutations which disrupt the MTS of PB2 were rescued
into recombinant influenza A/WSN/33 viruses (Fig. 4B). Cells
infected with these viruses displayed a predominantly nuclear
PB2 signal, although cytoplasmic staining could also be
detected in some cases. However, this cytoplasmic signal did
not represent PB2 localized to mitochondria, as determined by
the intensity plots across the merged images (Fig. 4B). We
speculate that this cytoplasmic signal could represent PB2
subunits of viral RNPs exported from the nucleus and targeted
to the cell membrane for viral assembly. Alternatively, it could
represent newly translated PB2 not yet transported into the
nucleus. A single leucine to alanine point mutation at residue 7
or 10 had little effect on the growth properties of the virus, but
substituting both leucine residues significantly reduced the
virus titer obtained from MDBK cells (Fig. 5A). This
attenuation in growth kinetics of the viruses is unlikely to be
caused by defects in polymerase activity, since introduction of
these point mutations did not cause dramatic changes to the
amount of viral vRNA, mRNA, and cRNA detected after
infection (Fig. 5B), nor were the levels of observed viral
proteins affected (Fig. 5C). Virus attenuation was also not due
to a defect in polymerase complex assembly, since the
efficiency with which PB2 protein co-purified with PB1 and
TAP-tagged PAwas unaffected by mutations in the MTS of PB2
(data not shown). With these possibilities excluded, the
attenuation in virus growth observed after the introduction of
mutations into the MTS of PB2 could be explained by the
effects such mutations might have on mitochondria-associated
functions of the protein.
The localization of PB2 to mitochondria during an
influenza virus infection raises questions about its possible
function at this cellular site. It seems unlikely that a
mitochondrial localization of PB2 is relevant for its polymer-
ase functions, since viral transcription and replication are
believed to take place in the nucleus of infected cells (Jackson
et al., 1982). Also, PB2 alone was detected at the mitochon-
dria. The PB1 and PA subunits could not be detected at this
site by fluorescence microscopy (data not shown). It is
probable that the PB2 of influenza viruses therefore has a
mitochondria-associated function which is unrelated to its
polymerase activity. To address the effect of PB2 on
mitochondrial function, the mitochondrial membrane potential
was monitored after infection with wild-type or recombinant
influenza A/WSN/33 viruses (Fig. 6). Viruses possessing point
mutations in the MTS of PB2, particularly the L7L10A
recombinant virus, caused a more dramatic disruption to the
mitochondrial membrane potential of infected cells than a
wild-type virus (Fig. 6B), suggesting that mitochondrial
function or membrane integrity was affected. Since the
mutations in the MTS of PB2 prevent localization of the
protein to mitochondria, this suggests a role for PB2 in
maintaining viable, functional mitochondria in infected cells.
There appears to be a relationship between mitochondrial
disruption and reduced viral titers. Wild-type influenza A/
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membrane potential (Fig. 6B) and can attain a high virus titer
in both MDBK cells (Fig. 5A) and a mouse model (Fig. 7C).
In contrast, the recombinant viruses cause a greater disruption
to mitochondrial membrane potential and have reduced viral
titers. Such a relationship suggests that influenza virus acts to
maintain mitochondrial function, and consequently energy
levels, throughout an infection to permit efficient generation of
new virus particles. For example, export of newly synthesized
viral ribonucleoprotein from the nucleus, and its transport to
the plasma membrane of infected cells is likely to involve
energy-dependent mechanisms. Moreover, the assembly of
new virus particles and the process of budding from the host
cell membrane may also have energy requirements dependent
on viable mitochondria. The molecular mechanism by which
PB2 would act to maintain mitochondrial function in infected
cells is unknown, but preliminary work by this group suggests
an interaction between PB2 and the mitochondrial protein p32.
This protein forms a trimeric complex in the mitochondrial
matrix (Jiang et al., 1999) and is thought to be involved in
mitochondrial oxidative phosphorylation (Muta et al., 1997),
although other non-mitochondrial functions have also been
suggested for the protein. It is tempting to speculate that
interactions between PB2 and p32 permit the regulation of
mitochondrial function.
Studies in a mouse model indicate that a wild-type influenza
A/WSN/33 virus infection induces significant pathogenicity,
affecting both survival rates and weight loss in mice (Figs. 7A
and B). Survival rates improved, and body weight changes
were reduced in mice infected with viruses possessing point
mutations in the MTS of PB2 (Figs. 7A and B; L7A, L10A,
and L7L10A viruses). This correlated with a reduction in
maximal viral titers obtained from the lungs of mice infected
with the recombinant viruses as compared to mice infected
with wild-type influenza A/WSN/33 (Fig. 7C). The inability of
the recombinant viruses to obtain as high a titer as a wild-type
virus would explain why they show a reduced pathogenicity in
a mouse model.
The PB2 protein of influenza virus is not the only viral
protein targeted to mitochondria during an infection. The PB1-
F2 protein of influenza A viruses, generated from the +1
reading frame of the mRNA coding for PB1, can also be
detected at the mitochondria of infected cells (Chen et al.,
2001). A mitochondrial-targeting signal has been identified
near the carboxyl terminus of the protein, and similar to PB2,
this signal was contained within a region of the protein
displaying an a-helical secondary structure of amphipathic
nature (Gibbs et al., 2003; Yamada et al., 2004). PB1-F2 is
known to be involved in the induction of apoptotic cell death
in a cell-line-dependent fashion (Chen et al., 2001; Gibbs et
al., 2003; Yamada et al., 2004; Zamarin et al., 2005). It is
possible that PB2 may also influence the outcome of an
apoptotic response via its mitochondrial targeting. In fact,
Morris et al. (2005) recently suggested a role for PB2 in
determining apoptosis in infected cells. Our experiments using
viral infection with wild-type or recombinant viruses, to
determine the potential role of PB2 in regulating apoptosis,did not result in conclusive evidence for a pro- or anti-
apoptotic function (data not shown). However, it is important
to note that several influenza viral proteins are proposed to
influence an apoptotic response (reviewed in Lowy, 2003),
highlighting the complexity faced when attempting to inves-
tigate the contribution of a single viral protein towards
apoptosis regulation. Indeed, Morris et al. (2005) concluded
that influenza virus induced apoptosis is a multi-factorial
process.
In an attempt to confirm the role of PB2 in maintaining
mitochondrial viability, we have also investigated whether PB2
expression alone can maintain the mitochondrial membrane
potential of cells (data not shown). However, such experiments
were complicated by the observation that PB2 is mildly
cytotoxic when expressed in cells from a plasmid containing a
strong promoter. The reason for this cytotoxicity is unknown,
but it is important to note that it was not related to the
mitochondrial localization of PB2, since similar effects were
observed in cells after the expression of wild-type PB2 or L7A,
L10A, and L7L10A containing PB2 proteins (data not shown).
Nevertheless, this complication prevented us from determining
if the maintenance of mitochondrial membrane potential by PB2
is a property inherent to the protein, or is only associated with
the protein specifically during an influenza virus infection.
Discrepancies in results obtained from experiments using
individual protein expression or viral infections are not
uncommon. For example, the influenza virus non-structural
protein 1 (NS1) has been shown to down-regulate apoptosis in
infected cells (Zhirnov et al., 2002), but when expressed alone
in transfected cells NS1 induces apoptosis (Schultz-Cherry et
al., 2001).
PB1-F2 was found to induce the loss of mitochondrial
membrane potential (Chen et al., 2001; Gibbs et al., 2003),
while we suggest here that PB2 prevents mitochondrial
potential loss. Thus, PB2 would act antagonistically to PB1-
F2. We speculate that if the main role of PB1-F2 were to act as
an excreted peptide on immune cells recruited to the site of
infection, as suggested by Chen et al. (2001), PB2 might
counteract the negative mitochondrial effect of PB1-F2 in the
infected cells. While mitochondrial PB2 and PB1-F2 can both
be detected in infected cells, it is unknown whether the two
proteins interact at this site and if such an interaction modulates
the function of both proteins. An interaction between PB2 and
PB1-F2 certainly is not required for localization of either
protein to mitochondria, since both contain MTSs and both can
be detected at the mitochondria when expressed individually in
cells from plasmids (Fig. 1A and Chen et al., 2001).
The data presented in this report suggest that the PB2
protein of influenza viruses has a role at the mitochondria of an
infected cell, in addition to its previously described function as
a polymerase subunit. Since influenza viruses only encode for a
small number of viral proteins, it is likely that each has multiple
functions which permit the virus to take advantage of the
resources of the host cell. PB2, by interacting either directly
with mitochondrial membranes or with a mitochondrial protein,
could regulate the viability of mitochondria during an influenza
virus infection. We suggest that the maintenance of mitochon-
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which new virus is produced.
Materials and methods
Plasmids
The pcDNA-PB1, pcDNA-PB2, and pcDNA-PA expression
plasmids for the three polymerase subunits of influenza A/
WSN/33 virus; a pcDNA-PB2 expression plasmid for PB2 of
influenza A/PR/8/34 virus (Cambridge variant); and pcDNA-
GFP have been described elsewhere (Fodor et al., 2002;
Subbarao et al., 2003). pcDNA-PB2-GFP, pcDNA-GFP-PB2,
and pcDNA-PB2-FLAG have also been described (Fodor and
Smith, 2004). pcDNA-PA-TAP was generated by inserting the
tandem affinity purification (TAP) sequence (Puig et al., 2001)
into the NotI/XbaI sites of pcDNA-PA-GFP (Fodor and Smith,
2004), after removal of the GFP ORF with the same restriction
enzymes. pcDNA-polIpolII-PB2 (A/Turkey/England/5092/91)
and pcDNA-PB2 (B/AnnArbor/1/66) were donated by W.
Barclay (University of Reading, UK).
Plasmids expressing influenza A/WSN/33 virus PB2 frag-
ments 1–22, 1–60, 1–120, 1–180, 1–281, and 1–522 tagged
with GFP were generated by inserting PCR products from a
pcDNA-PB2 template into the BamHI/NotI sites of pcDNA-
GFP. Plasmids expressing PB2 fragments 23–759, 61–759,
121–759, and 181–759 tagged with GFP were generated by
inserting PCR products from a pcDNA-PB2 template into the
BamHI/BstEII sites of pcDNA-PB2-GFP after removal of the
relevant region of PB2 with the same enzymes. R3A-, L7A-,
R8A-, L10A-, S12P-, S14A-, and R15A-GFP expression
plasmids were generated by site-directed mutagenesis using
appropriate primers and a pcDNA-PB2-GFP template with the
QuickChange Site Directed Mutagenesis Kit (Stratagene),
according to the manufacturer’s instructions. L7L10A-GFP
was generated in a similar fashion using pcDNA-L7A-GFP as
a template for the PCR. All primer sequences can be provided
upon request.
Antibodies
Antibodies used were rabbit polyclonal anti-PB2 (gift from
T. Toyoda, Kurume University, Japan), mouse monoclonal
anti-PB2 (PB2.25) (gift from A. Portela, Instituto de Salud
Carlos III, Madrid, Spain) (Ba´rcena et al., 1994), mouse
monoclonal anti-cytochrome c antibody (clone 6H2.B4) (BD
Pharmingen), rabbit polyclonal anti-influenza A turkey anti-
bodies (gift from O. Haller, Freiburg University, Germany)
(Haller et al., 1976), rabbit polyclonal anti-NS1 (Talon et al.,
2000), and mouse monoclonal anti-FLAG M2 antibody
(Sigma). An Escherichia coli expressed his-tagged fragment
of PB2 (A/WSN/33) (amino acids 1–180) was used to
immunize rabbits to obtain anti-PB2 polyclonal sera (Euro-
gentec). An E. coli expressed his-tagged fragment of PA (A/
WSN/33) (amino acids 490–716) was used to obtain anti-PA
polyclonal sera by a similar method (gift from T. Deng,
University of Oxford, UK).Immunofluorescence
Vero, HeLa, Cos-7, and MDCK cells were grown as
monolayers on 13-mm coverslips in 24-well plates. 293T cells
were grown on 22 mm fibronectin-coated coverslips (BD
BioSciences) to aid attachment. Cells were infected or
transfected as appropriate at approximately 70–80% con-
fluency. Transfection was performed using 1 Ag of the
appropriate expression plasmid with 2 Al of Lipofectamine
2000 transfection reagent according to the manufacturer’s
instructions (Invitrogen). Cells were incubated overnight at
37 -C (approximately 16 h). Infection was performed with
influenza A/PR/8/34 virus, influenza A/WSN/33 virus, or
recombinant influenza A/WSN/33 viruses possessing mutations
in the PB2 gene segment, at an m.o.i. of 1. Cells were incubated
for 8 h at 37 -C. Both transfected and infected cells were
stained with 100 nM MitoTracker Red CMXRos (Molecular
Probes) for 30 min prior to further treatment. For detection of
GFP, cells were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 15 min and coverslips were mounted
in Mowiol (Calbiochem). For indirect immunofluorescence,
following fixation, cells were permeabilized in 0.5% Triton X-
100 in PBS for 15 min, blocked in PBS* (PBS; 1% bovine
serum albumin; 0.2% gelatin; 0.1% Tween-20, pH 8.0), and
incubated with the corresponding antibodies in PBS* for 1 h.
Non-tagged PB2 was detected with rabbit polyclonal anti-PB2
or mouse monoclonal anti-PB2 antibodies. FITC- and Cy2-
conjugated anti-rabbit and anti-mouse antibodies (Jackson
ImmunoResearch Laboratories) were used as secondary anti-
bodies. Cytochrome c was detected with mouse monoclonal
antibodies using Cy3-conjugated anti-mouse secondary anti-
bodies. Coverslips were mounted in Mowiol and cells were
viewed using a Zeiss Axioplan microscope fitted with a Spot
CCD camera (Spot Diagnostic Instruments) with a63/1.25 oil
immersion objective. Images were recorded and exported to
Adobe Photoshop 6.0 where they were overlaid electronically.
Alternatively, cells were viewed using a Bio-Rad MRC 1024
confocal microscope with a 60/1.40 oil immersion objective.
Individual channel (Cy2/FITC/GFP, Cy3) images were
recorded separately using Kalman filtering, before export to
Adobe Photoshop for further processing. As an indicator of co-
localization, signal intensities across a cellular distance for both
PB2 and MitoTracker Red, or PB2 and cytochrome c, was
plotted together using the line scan function of Metamorph
software (Universal Imaging). To quantitate the number of
infected or transfected cells displaying a mitochondrial
localization for PB2, a minimum of 10 random fields were
selected from appropriate experiments. Infected cells were
identified as those showing a nuclear PB2 signal after labeling
with rabbit polyclonal anti-PB2 antibody. The presence or lack
of a mitochondrial PB2 signal was recorded, as determined by
co-staining with MitoTracker Red.
Virus rescue and growth curves
The plasmid-based viral rescue technique (Fodor et al.,
1999, 2002; Neumann et al., 1999) was used to generate
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viruses. Briefly, PB2 point mutations were introduced into
pPOLI-PB2-RT by site-directed mutagenesis with the appro-
priate primers. These constructs were transfected into 293T
cells in suspension along with 7 pPOLI plasmids corresponding
to the other 7 viral gene segments, using Lipofectamine 2000.
The three influenza virus polymerase proteins and the
nucleoprotein were expressed from pcDNA-PB1, -PB2, -PA,
and -NP, respectively. Virus was collected from the tissue
culture medium 48 h post-transfection and amplified for a
further 24–48 h on MDBK cells.
Wild-type and recombinant influenza A/WSN/33 viruses
were used to infect MDBK cells in 35 mm dishes at an m.o.i. of
0.001. Released virus was collected from the culture medium
every 12 h and plaque assayed on MDBK cells to determine the
viral titer. Viral plaques were stained with a Coomassie blue
solution (0.25% Coomassie, 50% methanol, 10% acetic acid)
to permit measurement of plaque size. Between 40 and 50 viral
plaques were counted for each virus, and plaque size was
expressed as the mean, with standard deviations shown. Two-
tailed Student’s t tests were performed on all data to determine
the significance of the results.
Analysis of vRNA, mRNA, and cRNA by primer extension
assays
MDBK cells grown as monolayers in 35 mm dishes were
infected with wild-type or recombinant influenza A/WSN/33
viruses at an m.o.i. of 4. Cells were harvested 6 h post-
infection, and total RNA was isolated using TRIzol reagent
(Invitrogen). Primer extension assays were performed as
described previously (Fodor et al., 2002). Briefly, RNA was
reverse transcribed using SuperScript II reverse transcriptase
(Invitrogen) and two radio-labeled NA-specific primers
(Vreede et al., 2004), to detect vRNA, mRNA, and cRNA
in the same transcription reaction. Transcription products
were analyzed on 6% polyacrylamide gels, containing 7 M
urea, and detected on a Fujifilm FLA-5000 fluorescent image
analyzer, using Fujifilm Imaging Plates (Fuji Photo Film
Co.). mRNA-specific transcription products were approxi-
mately 169 nucleotides (nt) in size. cRNA- and vRNA-
specific products were 160 nt and 129 nt, respectively. Data
from 3 separate experiments were exported and quantified in
AIDA software (Raytest), and values were converted to
mean percentage activity as compared to wild-type and
presented in graphical format using Excel (Microsoft). The
significance of the data was tested using a two-tailed one-
sample t test.
Assay for polymerase subunit interaction
293T cells (approximately 106 cells) were transfected in
suspension with 1 Ag each of pcDNA-PA-TAP, pcDNA-PB1,
and pcDNA-PB2 or pcDNA-PB2-GFP (wild-type or
mutants) using 6 Al of Lipofectamine 2000 transfection
reagent. The TAP method (Puig et al., 2001) was used to
purify PA and interacting PB1 and PB2. 36 h post-transfection, cells were harvested and cell lysates prepared
as described previously (Fodor and Smith, 2004). PA-TAP
and interacting proteins were purified by incubating the cell
lysates with immunoglobulin G (IgG)–sepharose. Proteins
were cleaved from the IgG–sepharose with 20 U of tobacco
etch virus protease (Invitrogen). Purified proteins were
analyzed by silver staining of sodium dodecyl sulphate
(SDS)–polyacrylamide gel electrophoresis (PAGE) gels with
the SilverXpress kit (Invitrogen), as per the manufacturer’s
instructions.
Analysis of mitochondrial membrane potential
Approximately 106 HeLa or MDBK cells grown as
monolayers in 35-mm dishes were infected with wild-type
or recombinant influenza A/WSN/33 viruses at an m.o.i. of 2,
4, 6, or 8 as appropriate. Alternatively, the cells were treated
with 0.5–1 AM staurosporine (Sigma) to induce apoptosis.
8–16 h post-infection, cells were collected by trypsin
treatment and centrifugation. Cells were washed once in
1% BSA in PBS and centrifuged prior to re-suspension in
500 Al of 1% BSA in PBS containing 500 nM TMRE
(Molecular Probes). Cells were incubated for 60 min at 37 -C
in the dark. Cells were centrifuged and re-suspended in 1%
BSA in PBS without TMRE, prior to analysis on a FACScan
cytometer (BD Biosciences) using a 488-nm laser. 105 cells
from each sample were counted, and the TMRE signal was
acquired in channel FL-2. Untreated cells stained with TMRE
were used as a control to determine the normal mitochondrial
membrane potential (mmp) in healthy cells. The percentage
of cells showing a reduced mmp after infection with wild-
type or recombinant influenza A/WSN/33 viruses was
calculated using CellQuest (BD Biosciences). Background
levels of reduced mmp as seen in the TMRE control were
subtracted from each test sample to generate a final value.
Data from 3 independent experiments were used to calculate
a mean percentage of cells with reduced mmp, which was
presented in graphical format using Excel (Microsoft). The
significance of the data was tested using a two-tailed
Student’s t test.
Western blotting
HeLa cells grown as monolayers in 35 mm dishes were
infected with wild-type or recombinant influenza A/WSN/33
viruses at an m.o.i. of 2 or 4 as appropriate. 16 h post-infection,
cell lysates were prepared as described previously (Fodor and
Smith, 2004). An equal volume of SDS–PAGE loading buffer
was added to the cell lysates, prior to boiling for 5 min. Viral
protein expression was analyzed by SDS–PAGE and Western
blotting with rabbit polyclonal anti-PB2 (amino acids 1–180),
rabbit polyclonal anti-PA (amino acids 490–716), rabbit
polyclonal anti-influenza A turkey, and rabbit polyclonal
anti-NS1 antibodies. The signal from peroxidase-conjugated
anti-rabbit secondary antibodies (Sigma) was detected using
the SuperSignal West Dura Extended Duration Substrate
(Pierce).
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Infections in mice were carried out as described previously
(Solorzano et al., 2000). Briefly, groups of 5 BALB/c mice
were inoculated with 104 pfu of wild-type or recombinant
influenza A/WSN/33 viruses and animals were monitored daily
for body weight changes and euthanized when observed in
extremis. In addition, virus was isolated from the lungs of
groups of 3 mice, at 3 and 6 days post-infection, for the
determination of lung titers (Solorzano et al., 2000). All
procedures were in accord with NIH guidelines on care and use
of laboratory animals. The significance of the results was tested
using a two-tailed Student’s t test.
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